Amgen’s Evenity osteoporosis treatment priced at $21,900 per year
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
5 fun places to hold a corporate gathering in the Tri-Counties
Building a great team starts with building morale and camaraderie. From activities that push you outside the office to tasks that engage your critical thinking skills at full throttle, team retreats are a way to have productive fun. Across the Tri-Counties, both indoor and outdoor spaces for corporate retreats and team-building exercises abound. Here are Read More →
Vo: Patents not the key to attracting investors
By Dan Vo One challenge faced by many entrepreneurs is to convince the investors, mostly angels and venture capitalists, that their startup is investment worthy. A lack of track record obviously does not help. So, it is often the case that when it is time to attract external investors, entrepreneurs look for possible ways to Read More →
Amgen gets FDA approval for osteoporosis drug Evenity
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Maxon acquires Redshift Rendering Technologies
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
inVia expands deal to supply robots for warehousing
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen, Novartis sue each other over migraine drug Aimovig
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
